Blood Culture Tests Market

研究執行與發布：MarketsandMarkets　·　發布日期 2026-08-12　·　372 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

Blood Culture Tests Market by Product (Consumables, Instruments), Method (Manual, Automated), Technology (Culture-Based, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospital, Academic Research), Region - Global Forecast to 2031

報告摘要

The global blood culture tests market is anticipated to grow from USD 6.66 billion in 2026 to USD 8.94 billion by 2031, reflecting a CAGR of 6.1%. Market growth is supported by the rising incidence of bloodstream infections (BSIs), sepsis, and healthcare-associated infections (HAIs), along with increasing concerns regarding antimicrobial resistance (AMR). Blood culture remains an important diagnostic approach for detecting viable microorganisms in the bloodstream and supporting appropriate antimicrobial treatment decisions. The increasing number of hospital admissions, surgical procedures, and critically ill and immunocompromised patients is further contributing to blood culture testing volumes. Additionally, the growing adoption of automated blood culture systems, rapid microbial identification technologies, and integrated microbiology workflows, coupled with expanding diagnostic laboratory infrastructure, is accelerating market growth. “Consumables to register the highest CAGR in the blood culture tests market from 2026 to 2031” Based on product, the consumables segment is likely to record the highest CAGR during the forecast period. This segment is primarily driven by the recurring utilization of blood culture bottles, culture media, reagents, and other associated consumables required for routine blood culture testing. Unlike instruments, which are generally capital purchases with relatively long replacement cycles, blood culture bottles and related consumables are required for each test, creating sustained demand in proportion to testing volumes. Increasing diagnosis of sepsis and bloodstream infections, rising hospital and critical care admissions, and greater emphasis on early identification of causative pathogens are contributing to higher consumption across hospital microbiology and diagnostic laboratories. Furthermore, the expanding installed base of automated blood culture platforms is generating recurring demand for compatible aerobic, anaerobic, and pediatric blood culture bottles and media, further strengthening the segment’s position in the global market. “Bacteremia segment captured the largest share of the blood culture tests market in 2025” Based on application, the bacteremia segment accounted for the largest market share in 2025, owing to the widespread use of blood cultures for the detection of bacterial bloodstream infections and identification of causative pathogens. Bacteremia can occur secondary to infections originating from the respiratory tract, urinary tract, gastrointestinal tract, skin and soft tissues, as well as from intravascular catheters and other invasive procedures, resulting in substantial testing demand across hospital settings. Blood culture remains a key diagnostic method for confirming viable bacteria in the bloodstream and obtaining isolates for subsequent pathogen identification and antimicrobial susceptibility testing (AST). “Asia Pacific to register fastest growth rate in blood culture tests market between 2026 and 2031” Based on region, Asia Pacific is expected to witness the fastest growth rate during the forecast period. The regional market growth is supported by expanding healthcare infrastructure, increasing healthcare expenditure, and continued development of hospital and clinical laboratory capabilities across emerging economies. The substantial burden of infectious diseases, bloodstream infections, sepsis, and healthcare-associated infections, coupled with large patient populations and increasing hospital admissions, is driving demand for blood culture testing across the region. Governments and private healthcare providers are investing in diagnostic laboratory infrastructure, microbiology capabilities, hospital capacity, and healthcare accessibility, supporting a gradual transition from conventional workflows toward automated blood culture systems in several markets. Furthermore, growing awareness of antimicrobial resistance, antimicrobial stewardship, and the importance of early pathogen identification, along with increasing adoption of automated microbiology platforms and rapid diagnostic technologies, is contributing to market expansion. Major countries supporting regional growth include China, India, Japan, South Korea, and other rapidly developing Asia Pacific healthcare markets. Breakdown of primary participants in the blood culture tests market is as follows: • By Company Type: Tier 1 (31%), Tier 2 (40%), and Tier 3 (29%) • By Designation: C-level Executives (30%), Directors (24%), and Others (46%) • By Region: North America (52%), Europe (20%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) Key players in the blood culture tests market are Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), DiaSorin S.p.A. (Italy), Danaher Corporation (US), Bruker Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Accelerate Diagnostics, Inc (US), and Autobio Diagnostics Co., Ltd (China). Research Coverage: This research report categorizes the blood culture tests market by product (consumables, instruments, and software & services), method (conventional/manual blood culture and automated blood culture), technology (culture-based, molecular, and proteomics), application (bacteremia, fungemia, and mycobacterial detection), end user (hospital laboratories, reference laboratories, academic research laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the blood culture tests market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the market. This report covers the competitive analysis of upcoming startups in the blood culture tests ecosystem. Reasons to Buy This Report: The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall blood culture tests market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (Increasing number of sepsis patients and cost of treatment, Rapid growth in geriatric population with chronic diseases, High incidence of nosocomial bloodstream infections, Growing demand for rapid diagnostic techniques with faster turnaround times, High prevalence of infectious diseases globally), restraints (High cost of automated blood culture instruments, Lack of trained laboratory technicians) opportunities (Growth opportunities in emerging economies, Increased need to identify antibiotic-resistant microorganisms) and Challenges (Long turnaround time associated with conventional blood culture workflows, Blood culture contamination and pre-analytical errors) influencing the blood culture tests market growth • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the blood culture tests market • Market Development: Comprehensive information about lucrative markets; the report analyzes the blood culture tests market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood culture tests market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), and DiaSorin S.p.A. (Italy)

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 38 1.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.3 STUDY SCOPE 39 1.3.1 MARKETS COVERED & REGIONAL SCOPE 39 1.3.2 INCLUSIONS & EXCLUSIONS 40 1.3.3 YEARS CONSIDERED 41 1.4 CURRENCY CONSIDERED 41 1.5 STAKEHOLDERS 41 1.6 SUMMARY OF CHANGES 42 2 EXECUTIVE SUMMARY 43 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 43 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 44 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 45 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 46 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 47 3 PREMIUM INSIGHTS 48 3.1 BLOOD CULTURE TESTS MARKET OVERVIEW 48 3.2 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2026 VS. 2031 49 3.3 BLOOD CULTURE TESTS MARKET, BY METHOD, 2026 VS. 2031 49 3.4 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2026 VS. 2031 50 3.5 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2026 VS. 2031 50 3.6 BLOOD CULTURE TESTS MARKET, BY END USER, 2026 VS. 2031 51 3.7 BLOOD CULTURE TESTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51 4 MARKET OVERVIEW 52 4.1 INTRODUCTION 52 4.2 MARKET DYNAMICS 52 4.2.1 DRIVERS 53 4.2.1.1 Increasing number of sepsis patients and rising cost of treatment 53 4.2.1.2 Rapid growth in geriatric population with chronic diseases 53 4.2.1.3 High incidence of bloodstream infections 53 4.2.1.4 Growing demand for rapid diagnostic techniques 54 4.2.1.5 High prevalence of infectious diseases 54 4.2.2 RESTRAINTS 55 4.2.2.1 High cost of automated blood culture instruments 55 4.2.2.2 Lack of trained laboratory technicians 56 4.2.3 OPPORTUNITIES 56 4.2.3.1 Growth opportunities in emerging economies 56 4.2.3.2 Increased need to identify antibiotic-resistant microorganisms 57 4.2.4 CHALLENGES 57 4.2.4.1 Long turnaround time associated with conventional blood culture workflows 57 4.2.4.2 Blood culture contamination and pre-analytical errors 58 4.3 UNMET NEEDS & WHITE SPACES 58 4.3.1 UNMET NEEDS IN BLOOD CULTURE TESTS MARKET 58 4.3.2 WHITE SPACE OPPORTUNITIES 59 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60 4.4.1 INTERCONNECTED MARKETS 60 4.4.2 CROSS-SECTOR OPPORTUNITIES 61 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 62 4.5.1 KEY MOVES & STRATEGIC FOCUS 62 5 INDUSTRY TRENDS 63 5.1 PORTER’S FIVE FORCES ANALYSIS 63 5.1.1 BARGAINING POWER OF SUPPLIERS 64 5.1.2 BARGAINING POWER OF BUYERS 64 5.1.3 THREAT OF NEW ENTRANTS 64 5.1.4 THREAT OF SUBSTITUTES 64 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 64 5.2 MACROECONOMIC INDICATORS 65 5.2.1 INTRODUCTION 65 5.2.2 GDP TRENDS & FORECAST 65 5.3 SUPPLY CHAIN ANALYSIS 66 5.4 VALUE CHAIN ANALYSIS 68 5.5 ECOSYSTEM ANALYSIS 69 5.5.1 BLOOD CULTURE TESTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70 5.6 PRICING ANALYSIS 70 5.6.1 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY KEY PLAYER, 2024–2026 71 5.6.2 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY REGION, 2024–2026 72 5.7 TRADE ANALYSIS 73 5.7.1 IMPORT SCENARIO (HS CODE 382100) 73 5.7.2 EXPORT SCENARIO (HS CODE 382100) 74 5.8 KEY CONFERENCES & EVENTS, 2026–2027 74 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75 5.10 INVESTMENT & FUNDING SCENARIO 76 5.11 CASE STUDY ANALYSIS 76 5.11.1 ENHANCED STAINING AND WORKFLOW PROTOCOLS IMPROVE DETECTION OF FASTIDIOUS ORGANISMS IN POSITIVE BLOOD CULTURES 76 5.11.2 RAPID BLOOD CULTURE IDENTIFICATION AND ANTIMICROBIAL STEWARDSHIP REDUCE TIME TO OPTIMAL THERAPY 77 5.12 IMPACT OF 2025 US TARIFFS ON BLOOD CULTURE TESTS MARKET 78 5.12.1 INTRODUCTION 78 5.12.2 KEY TARIFF RATES 78 5.12.3 PRICE IMPACT ANALYSIS 79 5.12.4 IMPACT ON REGION 79 5.12.4.1 North America 79 5.12.4.2 Europe 79 5.12.4.3 Asia Pacific 79 5.12.5 IMPACT ON END-USE INDUSTRIES 80 5.12.5.1 Hospital laboratories 80 5.12.5.2 Reference laboratories 80 5.12.5.3 Academic research laboratories 80 5.12.5.4 Other end users 80 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81 6.1 KEY TECHNOLOGIES 81 6.1.1 CULTURE-BASED TECHNOLOGIES 81 6.1.2 MOLECULAR TECHNOLOGIES 81 6.2 COMPLEMENTARY TECHNOLOGIES 81 6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING 81 6.3 TECHNOLOGY/PRODUCT ROADMAP 82 6.4 PATENT ANALYSIS 83 6.4.1 LIST OF MAJOR PATENTS 84 6.5 FUTURE APPLICATIONS 84 6.6 IMPACT OF AI/GENERATIVE AI ON BLOOD CULTURE TESTS MARKET 85 6.6.1 INTRODUCTION 85 6.6.2 TOP USE CASES & MARKET POTENTIAL 86 6.6.3 KEY COMPANIES IMPLEMENTING AI 87 6.6.4 FUTURE OF AI 87 7 SUSTAINABILITY & REGULATORY LANDSCAPE 88 7.1 REGIONAL REGULATIONS & COMPLIANCE 88 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 7.1.2 INDUSTRY STANDARDS 90 7.2 SUSTAINABILITY INITIATIVES 91 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN BLOOD CULTURE TESTS 91 7.2.1.1 Eco-friendly initiatives 91 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 92 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 93 8.1 DECISION-MAKING PROCESS 93 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 93 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 93 8.2.2 BUYING CRITERIA 94 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94 8.4 UNMET NEEDS ACROSS VARIOUS END USERS 96 8.5 MARKET PROFITABILITY 97 8.5.1 REVENUE POTENTIAL 97 8.5.2 COST DYNAMICS 97 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 97 9 BLOOD CULTURE TESTS MARKET, BY OFFERING 99 9.1 INTRODUCTION 100 9.2 CONSUMABLES 100 9.2.1 BLOOD CULTURE MEDIA 102 9.2.1.1 Aerobic blood culture media 105 9.2.1.1.1 Growing blood culture volumes to support aerobic media market growth 105 9.2.1.2 Pediatric aerobic blood culture media 108 9.2.1.2.1 Rising pediatric sepsis burden to drive demand for specialized low-volume blood culture bottles 108 9.2.1.3 Anaerobic blood culture media 110 9.2.1.3.1 Increased need for routine diagnosis of bacteria in blood culture to drive segment 110 9.2.1.4 Mycobacterial blood culture media 113 9.2.1.4.1 Persistent global TB burden to drive demand for mycobacterial blood culture media 113 9.2.1.5 Fungi/yeast blood culture media 115 9.2.1.5.1 Easy identification and characterization of special fungal species to drive segment 115 9.2.2 ASSAY KITS & REAGENTS 117 9.2.2.1 Increased need for rapid identification of bacteria and yeast from positive blood cultures to drive market 117 9.2.3 BLOOD CULTURE ACCESSORIES 119 9.2.3.1 Growing number of blood culture tests to drive market 119 9.3 INSTRUMENTS 122 9.3.1 AUTOMATED BLOOD CULTURE SYSTEMS 125 9.3.1.1 Need for automated imaging systems and advanced algorithms to drive market 125 9.3.2 SUPPORTING LABORATORY EQUIPMENT 128 9.3.2.1 Incubators 130 9.3.2.1.1 Incubators to provide optimal environment with adequate temperature and oxygen levels for microbial growth 130 9.3.2.2 Colony counters 132 9.3.2.2.1 Colony counters to increase direct image scanning and analysis capability 132 9.3.2.3 Microscopes 134 9.3.2.3.1 Growing emphasis on rapid preliminary identification to fuel demand for microscopes 134 9.3.2.4 Gram stainers 136 9.3.2.4.1 Gram strainers to guide initial antibiotic section and appropriate empirical therapy 136 9.3.2.5 Other supporting equipment 139 9.4 SOFTWARE & SERVICES 141 9.4.1 INCREASED NEED FOR AUTOMATED SYSTEMS IN HOSPITAL-BASED LABORATORIES TO DRIVE MARKET 141 10 BLOOD CULTURE TESTS MARKET, BY METHOD 144 10.1 INTRODUCTION 145 10.2 CONVENTIONAL/MANUAL BLOOD CULTURES 145 10.2.1 LOWER CAPITAL REQUIREMENTS TO DRIVE ADOPTION OF CONVENTIONAL BLOOD CULTURE METHODS IN RESOURCE-CONSTRAINED SETTINGS 145 10.3 AUTOMATED BLOOD CULTURES 148 10.3.1 NEED FOR FASTER TURNAROUND TIMES TO FUEL TRANSITION TOWARD AUTOMATED BLOOD CULTURE METHODS 148 11 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY 152 11.1 INTRODUCTION 153 11.2 CULTURE-BASED TECHNOLOGIES 153 11.2.1 ADVANCEMENTS IN AUTOMATED DETECTION TO STRENGTHEN CULTURE-BASED TECHNOLOGIES SEGMENT 153 11.3 MOLECULAR TECHNOLOGIES 156 11.3.1 PCR 158 11.3.1.1 Reduced risk of contamination and easy detection of bloodstream infections to drive segment 158 11.3.2 MICROARRAYS 161 11.3.2.1 Determination of better genotyping characterization and identification of bacterial infections to drive segment 161 11.3.3 PNA-FISH 163 11.3.3.1 Rapid species-level identification to strengthen role of PNA-FISH in bloodstream infection diagnosis 163 11.4 OTHER TECHNOLOGIES 165 12 BLOOD CULTURE TESTS MARKET, BY APPLICATION 168 12.1 INTRODUCTION 169 12.2 BACTEREMIA 169 12.2.1 GROWING INCIDENCE OF SEPSIS CASES GLOBALLY TO DRIVE MARKET 169 12.3 FUNGEMIA 171 12.3.1 INCREASING INCIDENCE OF BLOODSTREAM INFECTIONS TO DRIVE MARKET 171 12.4 MYCOBACTERIAL DETECTION 174 12.4.1 HIGH GLOBAL TB BURDEN AND CONCENTRATION OF CASES IN HIGH-RISK POPULATIONS TO DRIVE DEMAND 174 13 BLOOD CULTURE TESTS MARKET, BY END USER 177 13.1 INTRODUCTION 178 13.2 HOSPITAL LABORATORIES 178 13.2.1 INCREASED ABILITY TO CONDUCT LARGE VOLUME OF BLOOD CULTURE TESTS TO DRIVE MARKET 178 13.3 REFERENCE LABORATORIES 181 13.3.1 GROWING REFERRAL AND SPECIALIZED TESTING NEEDS TO FUEL REFERENCE LABORATORY DEMAND 181 13.4 ACADEMIC RESEARCH LABORATORIES 183 13.4.1 GROWING FOCUS ON NOVEL DIAGNOSTIC DEVELOPMENT TO FUEL BLOOD CULTURE TESTING IN RESEARCH LABORATORIES 183 13.5 OTHER END USERS 185 14 BLOOD CULTURE TESTS MARKET, BY REGION 188 14.1 INTRODUCTION 189 14.2 NORTH AMERICA 190 14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 195 14.2.2 US 196 14.2.2.1 Rising sepsis burden and antimicrobial resistance to drive demand for blood culture testing in US 196 14.2.3 CANADA 200 14.2.3.1 Increasing MRSA bloodstream infection burden to strengthen demand 200 14.3 BLOOD CULTURE TESTS MARKET: VOLUME ANALYSIS 205 14.3.1 INTRODUCTION 205 14.3.2 NORTH AMERICA: BLOOD CULTURE SETS VOLUME 205 14.4 EUROPE 206 14.4.1 EUROPE: MACROECONOMIC OUTLOOK 210 14.4.2 GERMANY 211 14.4.2.1 Expanding healthcare investment and inpatient care spending to drive adoption 211 14.4.3 UK 215 14.4.3.1 Rising AMR-related bacteremia and E. coli prevalence to expand blood culture testing 215 14.4.4 FRANCE 219 14.4.4.1 Rising healthcare expenditure and high physician density to strengthen adoption 219 14.4.5 ITALY 223 14.4.5.1 Expanding microbiology surveillance and continued healthcare investment to support Italy’s market 223 14.4.6 SPAIN 228 14.4.6.1 Growing elderly population and healthcare utilization to sustain demand 228 14.4.7 REST OF EUROPE 232 14.5 ASIA PACIFIC 237 14.5.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 242 14.5.2 CHINA 242 14.5.2.1 Expanding healthcare investment and hospital capacity to drive blood culture testing demand in China 242 14.5.3 JAPAN 247 14.5.3.1 Extensive hospital infrastructure to sustain demand 247 14.5.4 INDIA 251 14.5.4.1 Rising government healthcare expenditure to support expansion of diagnostic and laboratory infrastructure 251 14.5.5 REST OF ASIA PACIFIC 255 14.6 LATIN AMERICA 260 14.6.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 264 14.6.2 BRAZIL 265 14.6.2.1 Growth in hospital-service expenditure to support modernization of Brazil's clinical diagnostic infrastructure 265 14.6.3 MEXICO 269 14.6.3.1 Strengthening AMR laboratory requirements to support adoption 269 14.6.4 REST OF LATIN AMERICA 273 14.7 MIDDLE EAST & AFRICA 278 14.7.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 278 15 COMPETITIVE LANDSCAPE 283 15.1 INTRODUCTION 283 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 283 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BLOOD CULTURE TESTS MARKET 283 15.3 REVENUE ANALYSIS, 2023–2025 285 15.4 MARKET SHARE ANALYSIS, 2025 285 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 288 15.5.1 STARS 288 15.5.2 EMERGING LEADERS 288 15.5.3 PERVASIVE PLAYERS 288 15.5.4 PARTICIPANTS 288 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 290 15.5.5.1 Company footprint 290 15.5.5.2 Region footprint 290 15.5.5.3 Offering footprint 291 15.5.5.4 Method footprint 291 15.5.5.5 Technology footprint 292 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 292 15.6.1 PROGRESSIVE COMPANIES 292 15.6.2 RESPONSIVE COMPANIES 292 15.6.3 DYNAMIC COMPANIES 293 15.6.4 STARTING BLOCKS 293 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 294 15.6.5.1 Detailed list of key startups/SMEs 294 15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 294 15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 295 15.7 COMPANY VALUATION & FINANCIAL METRICS 295 15.7.1 FINANCIAL METRICS 295 15.7.2 COMPANY VALUATION 296 15.8 BRAND/PRODUCT COMPARISON 296 15.9 COMPETITIVE SCENARIO 297 15.9.1 PRODUCT LAUNCHES & APPROVALS 297 15.9.2 DEALS 298 16 COMPANY PROFILES 299 16.1 KEY PLAYERS 299 16.1.1 WATERS CORPORATION 299 16.1.1.1 Business overview 299 16.1.1.2 Products offered 300 16.1.1.3 Recent developments 302 16.1.1.3.1 Product approvals 302 16.1.1.3.2 Deals 302 16.1.1.4 MnM view 303 16.1.1.4.1 Right to win 303 16.1.1.4.2 Strategic choices 303 16.1.1.4.3 Weaknesses & competitive threats 303 16.1.2 BIOMÉRIEUX 304 16.1.2.1 Business overview 304 16.1.2.2 Products offered 305 16.1.2.3 Recent developments 307 16.1.2.3.1 Product launches 307 16.1.2.4 MnM view 307 16.1.2.4.1 Right to win 307 16.1.2.4.2 Strategic choices 307 16.1.2.4.3 Weaknesses & competitive threats 307 16.1.3 THERMO FISHER SCIENTIFIC, INC. 308 16.1.3.1 Business overview 308 16.1.3.2 Products offered 309 16.1.3.3 Recent developments 310 16.1.3.3.1 Deals 310 16.1.3.4 MnM view 311 16.1.3.4.1 Right to win 311 16.1.3.4.2 Strategic choices 311 16.1.3.4.3 Weaknesses & competitive threats 311 16.1.4 DANAHER CORPORATION 312 16.1.4.1 Business overview 312 16.1.4.2 Products offered 313 16.1.4.3 MnM view 314 16.1.4.3.1 Right to win 314 16.1.4.3.2 Strategic choices 314 16.1.4.3.3 Weaknesses & competitive threats 314 16.1.5 F. HOFFMANN-LA ROCHE LTD. 315 16.1.5.1 Business overview 315 16.1.5.2 Products offered 316 16.1.5.3 Recent developments 317 16.1.5.3.1 Product launches 317 16.1.5.4 MnM view 318 16.1.5.4.1 Right to win 318 16.1.5.4.2 Strategic choices 318 16.1.5.4.3 Weaknesses & competitive threats 318 16.1.6 DIASORIN S.P.A. 319 16.1.6.1 Business overview 319 16.1.6.2 Products offered 320 16.1.6.3 Recent developments 322 16.1.6.3.1 Product approvals 322 16.1.7 BRUKER CORPORATION 323 16.1.7.1 Business overview 323 16.1.7.2 Products offered 324 16.1.7.3 Recent developments 325 16.1.7.3.1 Product launches & approvals 325 16.1.7.3.2 Deals 326 16.1.8 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 327 16.1.8.1 Business overview 327 16.1.8.2 Products offered 328 16.1.8.3 Recent developments 329 16.1.8.3.1 Product launches 329 16.1.9 AUTOBIO DIAGNOSTICS CO., LTD. 330 16.1.9.1 Business overview 330 16.1.9.2 Products offered 331 16.1.9.3 Recent developments 332 16.1.9.3.1 Deals 332 16.1.10 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD. 333 16.1.10.1 Business overview 333 16.1.10.2 Products offered 334 16.2 OTHER PLAYERS 335 16.2.1 HIMEDIA LABORATORIES PVT. LTD. 335 16.2.2 BIOBASE GROUP 336 16.2.3 LABOTRONICS SCIENTIFIC 337 16.2.4 HARDY DIAGNOSTICS 338 16.2.5 BIOLOG, INC. 339 16.2.6 ZHUHAI DEER BIOENGINEERING CO., LTD. 340 16.2.7 ZHUHAI MEIHUA MEDICAL TECHNOLOGY CO. LTD. 341 16.2.8 FISON INSTRUMENTS LTD. 342 16.2.9 BINDER GMBH 343 16.2.10 LABTRON EQUIPMENT LTD. 344 16.2.11 LABNICS LTD. 345 16.2.12 COPAN ITALIA S.P.A. 346 16.2.13 GREINER BIO-ONE INTERNATIONAL GMBH 347 16.2.14 LIOFILCHEM S.R.L. 348 16.2.15 TITAN BIOTECH LTD. 349 17 RESEARCH METHODOLOGY 350 17.1 RESEARCH DATA 350 17.2 RESEARCH APPROACH 350 17.2.1 SECONDARY RESEARCH 350 17.2.1.1 Key data from secondary sources 351 17.2.2 PRIMARY DATA 352 17.2.2.1 Key data from primary sources 354 17.2.2.2 Key industry insights 355 17.3 MARKET SIZE ESTIMATION 356 17.3.1 BOTTOM-UP APPROACH 357 17.3.1.1 Approach 1: Company revenue estimation approach 357 17.3.1.2 Approach 2: Presentations of companies and primary interviews 357 17.3.1.3 Growth forecast 358 17.3.2 TOP-DOWN APPROACH 358 17.4 MARKET BREAKDOWN & DATA TRIANGULATION 360 17.5 MARKET SHARE ANALYSIS 361 17.6 RESEARCH ASSUMPTIONS 361 17.6.1 GROWTH RATE ASSUMPTIONS 361 17.7 RESEARCH LIMITATIONS 362 17.8 RISK ASSESSMENT 362 18 APPENDIX 363 18.1 DISCUSSION GUIDE 363 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 368 18.3 CUSTOMIZATION OPTIONS 370 18.4 RELATED REPORTS 370 18.5 AUTHOR DETAILS 371

圖表清單 List of Tables & Figures

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010, 2023, AND 2024 (MILLION PEOPLE) 55 TABLE 2 TOTAL TUBERCULOSIS INCIDENCE, BY REGION, 2024 55 TABLE 3 BLOOD CULTURE TESTS MARKET: PORTER’S FIVE FORCES ANALYSIS 64 TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 65 TABLE 5 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 71 TABLE 6 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY REGION, 2024–2026 (USD) 72 TABLE 7 IMPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 73 TABLE 8 EXPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 74 TABLE 9 BLOOD CULTURE TESTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 74 TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 78 TABLE 11 LIST OF MAJOR PATENTS PERTAINING TO BLOOD CULTURE TESTS MARKET, 2023–2025 84 TABLE 12 KEY COMPANIES IMPLEMENTING AI IN BLOOD CULTURE TESTS MARKET 87 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 18 GLOBAL STANDARDS IN BLOOD CULTURE TESTS MARKET 90 TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 93 TABLE 20 KEY BUYING CRITERIA, BY OFFERING 94 TABLE 21 ADOPTION BARRIERS & INTERNAL CHALLENGES 95 TABLE 22 BLOOD CULTURE TESTS MARKET: UNMET NEEDS ACROSS VARIOUS END USERS 96 TABLE 23 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 100 TABLE 24 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 100 TABLE 25 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 101 TABLE 26 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 27 EUROPE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 28 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 102 TABLE 29 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 102 TABLE 30 EXAMPLES OF BLOOD CULTURE MEDIA 103 TABLE 31 BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 103 TABLE 32 BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 104 TABLE 33 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 34 EUROPE: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 35 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 36 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 37 AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 38 NORTH AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 106 TABLE 39 EUROPE: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 40 ASIA PACIFIC: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 41 LATIN AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 42 PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 43 NORTH AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 44 EUROPE: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 45 ASIA PACIFIC: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 46 LATIN AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 47 ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 48 NORTH AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 49 EUROPE: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 50 ASIA PACIFIC: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 51 LATIN AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 52 MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 53 NORTH AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 54 EUROPE: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 55 ASIA PACIFIC: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 56 LATIN AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 57 FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 58 NORTH AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 59 EUROPE: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 60 ASIA PACIFIC: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 61 LATIN AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 62 EXAMPLES OF BLOOD CULTURE ASSAY KITS & REAGENTS 117 TABLE 63 BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 64 NORTH AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 65 EUROPE: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 66 ASIA PACIFIC: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 67 LATIN AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 68 EXAMPLES OF BLOOD CULTURE ACCESSORIES 120 TABLE 69 BLOOD CULTURE ACCESSORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 70 NORTH AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 71 EUROPE: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 72 ASIA PACIFIC: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 73 LATIN AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 74 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 75 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 76 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 77 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 78 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 79 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 80 EXAMPLES OF AUTOMATED BLOOD CULTURE SYSTEMS 125 TABLE 81 AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 82 NORTH AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 83 EUROPE: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 84 ASIA PACIFIC: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 85 LATIN AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 86 SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 87 SUPPORTING LABORATORY EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 88 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 89 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 90 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 91 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 92 INCUBATORS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 93 NORTH AMERICA: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 94 EUROPE: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 95 ASIA PACIFIC: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 96 LATIN AMERICA: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 97 COLONY COUNTERS MARKET, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 98 NORTH AMERICA: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 99 EUROPE: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 100 ASIA PACIFIC: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 101 LATIN AMERICA: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 102 MICROSCOPES MARKET, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 103 NORTH AMERICA: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 104 EUROPE: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 105 ASIA PACIFIC: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 106 LATIN AMERICA: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 107 GRAM STAINERS MARKET, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 108 NORTH AMERICA: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 109 EUROPE: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 110 ASIA PACIFIC: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 111 LATIN AMERICA: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 112 OTHER SUPPORTING EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 113 NORTH AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 114 EUROPE: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 115 ASIA PACIFIC: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 116 LATIN AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 117 BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 118 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 119 EUROPE: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 120 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 121 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 122 BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 145 TABLE 123 EXAMPLES OF CONVENTIONAL/MANUAL BLOOD CULTURE PRODUCTS 146 TABLE 124 CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 125 NORTH AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 126 EUROPE: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 127 ASIA PACIFIC: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 128 LATIN AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 129 EXAMPLES OF AUTOMATED BLOOD CULTURE PRODUCTS 149 TABLE 130 AUTOMATED BLOOD CULTURES MARKET, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 131 NORTH AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 132 EUROPE: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 133 ASIA PACIFIC: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 134 LATIN AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 135 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 153 TABLE 136 BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 137 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 138 EUROPE: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 139 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 140 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 141 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 142 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 143 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 144 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 145 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 146 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 147 BLOOD CULTURE TESTS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 148 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 149 EUROPE: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 150 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 151 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 152 BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 153 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 154 EUROPE: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 155 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 156 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 157 BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 158 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 159 EUROPE: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 160 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 161 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 162 EXAMPLES OF MALDI-TOF MS SYSTEMS 166 TABLE 163 BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 164 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 165 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 166 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 167 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 168 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169 TABLE 169 BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 170 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 171 EUROPE: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 172 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 173 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 174 BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 175 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 176 EUROPE: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 177 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 178 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 179 BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 180 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 181 EUROPE: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 182 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 183 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 184 BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 178 TABLE 185 BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 186 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 187 EUROPE: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 188 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 189 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 190 BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 191 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 192 EUROPE: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 193 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 194 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 195 BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 196 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 197 EUROPE: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 198 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 199 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 200 BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 186 TABLE 201 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 202 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 203 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 204 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 205 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 206 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 207 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 192 TABLE 208 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 209 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 210 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 211 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 212 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 193 TABLE 213 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 194 TABLE 214 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 215 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194 TABLE 216 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 217 NORTH AMERICA: MACROECONOMIC INDICATORS 195 TABLE 218 US: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196 TABLE 219 US: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 220 US: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 221 US: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 222 US: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 223 US: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 198 TABLE 224 US: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199 TABLE 225 US: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 226 US: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 199 TABLE 227 US: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 228 CANADA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 201 TABLE 229 CANADA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 230 CANADA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 231 CANADA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 232 CANADA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 233 CANADA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 203 TABLE 234 CANADA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 203 TABLE 235 CANADA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 236 CANADA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204 TABLE 237 CANADA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 204 TABLE 238 NORTH AMERICA: BLOOD CULTURE SETS VOLUME, 2024–2031 (MN UNITS) 205 TABLE 239 EUROPE: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 240 EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207 TABLE 241 EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 242 EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 243 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 244 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 245 EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 208 TABLE 246 EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209 TABLE 247 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 248 EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 209 TABLE 249 EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 250 EUROPE: MACROECONOMIC INDICATORS 210 TABLE 251 GERMANY: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 211 TABLE 252 GERMANY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 253 GERMANY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 254 GERMANY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 255 GERMANY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 256 GERMANY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 213 TABLE 257 GERMANY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213 TABLE 258 GERMANY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 259 GERMANY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 214 TABLE 260 GERMANY: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 261 UK: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216 TABLE 262 UK: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 263 UK: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 264 UK: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 265 UK: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 266 UK: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 217 TABLE 267 UK: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 218 TABLE 268 UK: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 269 UK: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 270 UK: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 271 FRANCE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 220 TABLE 272 FRANCE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 273 FRANCE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 274 FRANCE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 275 FRANCE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 276 FRANCE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 221 TABLE 277 FRANCE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222 TABLE 278 FRANCE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 279 FRANCE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222 TABLE 280 FRANCE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 223 TABLE 281 ITALY: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 224 TABLE 282 ITALY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 283 ITALY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 284 ITALY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 285 ITALY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 286 ITALY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 226 TABLE 287 ITALY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 226 TABLE 288 ITALY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 289 ITALY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 227 TABLE 290 ITALY: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 291 SPAIN: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 228 TABLE 292 SPAIN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 293 SPAIN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 294 SPAIN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 295 SPAIN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 296 SPAIN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 230 TABLE 297 SPAIN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 230 TABLE 298 SPAIN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 299 SPAIN: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 231 TABLE 300 SPAIN: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 301 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 233 TABLE 302 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 303 REST OF EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 304 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 305 REST OF EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 306 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 235 TABLE 307 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235 TABLE 308 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 309 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236 TABLE 310 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 236 TABLE 311 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 312 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 238 TABLE 313 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 314 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 315 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 316 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 317 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 240 TABLE 318 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 319 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 320 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241 TABLE 321 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 241 TABLE 322 ASIA PACIFIC: MACROECONOMIC INDICATORS 242 TABLE 323 CHINA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 243 TABLE 324 CHINA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 325 CHINA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 326 CHINA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 327 CHINA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 328 CHINA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 245 TABLE 329 CHINA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245 TABLE 330 CHINA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 331 CHINA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 332 CHINA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 333 JAPAN: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 247 TABLE 334 JAPAN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 335 JAPAN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 336 JAPAN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 337 JAPAN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 338 JAPAN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 249 TABLE 339 JAPAN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249 TABLE 340 JAPAN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 341 JAPAN: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 342 JAPAN: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 343 INDIA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 251 TABLE 344 INDIA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 345 INDIA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 346 INDIA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 347 INDIA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 348 INDIA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 253 TABLE 349 INDIA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 253 TABLE 350 INDIA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 351 INDIA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 254 TABLE 352 INDIA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 353 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 256 TABLE 354 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 355 REST OF ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 356 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 357 REST OF ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 358 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 258 TABLE 359 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 258 TABLE 360 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 361 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 259 TABLE 362 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 363 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 364 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 261 TABLE 365 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 366 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 367 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 368 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 369 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 262 TABLE 370 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 263 TABLE 371 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 372 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263 TABLE 373 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 374 LATIN AMERICA: MACROECONOMIC INDICATORS 264 TABLE 375 BRAZIL: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 265 TABLE 376 BRAZIL: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 377 BRAZIL: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 378 BRAZIL: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 379 BRAZIL: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 380 BRAZIL: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 267 TABLE 381 BRAZIL: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 268 TABLE 382 BRAZIL: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 383 BRAZIL: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268 TABLE 384 BRAZIL: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 385 MEXICO: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 270 TABLE 386 MEXICO: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 387 MEXICO: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 388 MEXICO: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 389 MEXICO: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 390 MEXICO: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 271 TABLE 391 MEXICO: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272 TABLE 392 MEXICO: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 393 MEXICO: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272 TABLE 394 MEXICO: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 395 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 274 TABLE 396 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 397 REST OF LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 398 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 399 REST OF LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 400 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 276 TABLE 401 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276 TABLE 402 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 403 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277 TABLE 404 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 277 TABLE 405 MIIDLE EAST & AFERICA: MACROECONOMIC INDICATORS 279 TABLE 406 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 279 TABLE 407 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 408 MIDDLE EAST & AFRICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 409 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 410 MIDDLE EAST & AFRICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 411 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 281 TABLE 412 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 281 TABLE 413 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 414 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 415 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 282 TABLE 416 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BLOOD CULTURE TESTS MARKET, JANUARY 2023−AUGUST 2026 283 TABLE 417 BLOOD CULTURE TESTS MARKET: DEGREE OF COMPETITION 286 TABLE 418 BLOOD CULTURE TESTS MARKET: REGION FOOTPRINT 290 TABLE 419 BLOOD CULTURE TESTS MARKET: OFFERING FOOTPRINT 291 TABLE 420 BLOOD CULTURE TESTS MARKET: METHOD FOOTPRINT 291 TABLE 421 BLOOD CULTURE TESTS MARKET: TECHNOLOGY FOOTPRINT 292 TABLE 422 BLOOD CULTURE TESTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 294 TABLE 423 BLOOD CULTURE TESTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 294 TABLE 424 BLOOD CULTURE TESTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 295 TABLE 425 BLOOD CULTURE TESTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–AUGUST 2026 297 TABLE 426 BLOOD CULTURE TESTS MARKET: DEALS, JANUARY 2023–AUGUST 2026 298 TABLE 427 WATERS CORPORATION: COMPANY OVERVIEW 299 TABLE 428 WATERS CORPORATION: PRODUCTS OFFERED 300 TABLE 429 WATERS CORPORATION: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 302 TABLE 430 WATERS CORPORATION: DEALS, JANUARY 2023–JUNE 2026 302 TABLE 431 BIOMÉRIEUX: COMPANY OVERVIEW 304 TABLE 432 BIOMÉRIEUX: PRODUCTS OFFERED 305 TABLE 433 BIOMÉRIEUX: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 307 TABLE 434 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 308 TABLE 435 THERMO FISHER SCIENTIFIC, INC.: PRODUCTS OFFERED 309 TABLE 436 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2023–JUNE 2026 310 TABLE 437 DANAHER CORPORATION: COMPANY OVERVIEW 312 TABLE 438 DANAHER CORPORATION: PRODUCTS OFFERED 313 TABLE 439 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 315 TABLE 440 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 316 TABLE 441 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 317 TABLE 442 DIASORIN S.P.A.: COMPANY OVERVIEW 319 TABLE 443 DIASORIN S.P.A.: PRODUCTS OFFERED 320 TABLE 444 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 322 TABLE 445 BRUKER CORPORATION: COMPANY OVERVIEW 323 TABLE 446 BRUKER CORPORATION: PRODUCTS OFFERED 324 TABLE 447 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 325 TABLE 448 BRUKER CORPORATION: DEALS, JANUARY 2023–JUNE 2026 326 TABLE 449 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 327 TABLE 450 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 328 TABLE 451 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 329 TABLE 452 AUTOBIO DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 330 TABLE 453 AUTOBIO DIAGNOSTICS CO., LTD.: PRODUCTS OFFERED 331 TABLE 454 AUTOBIO DIAGNOSTICS CO., LTD.: DEALS, JANUARY 2023–JUNE 2026 332 TABLE 455 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 333 TABLE 456 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 334 TABLE 457 HIMEDIA LABORATORIES PVT. LTD.: COMPANY OVERVIEW 335 TABLE 458 BIOBASE GROUP: COMPANY OVERVIEW 336 TABLE 459 LABOTRONICS SCIENTIFIC: COMPANY OVERVIEW 337 TABLE 460 HARDY DIAGNOSTICS: COMPANY OVERVIEW 338 TABLE 461 BIOLOG, INC.: COMPANY OVERVIEW 339 TABLE 462 ZHUHAI DEER BIOENGINEERING CO., LTD.: COMPANY OVERVIEW 340 TABLE 463 ZHUHAI MEIHUA MEDICAL TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 341 TABLE 464 FISON INSTRUMENTS LTD.: COMPANY OVERVIEW 342 TABLE 465 BINDER GMBH: COMPANY OVERVIEW 343 TABLE 466 LABTRON EQUIPMENT LTD.: COMPANY OVERVIEW 344 TABLE 467 LABNICS LTD.: COMPANY OVERVIEW 345 TABLE 468 COPAN ITALIA S.P.A.: COMPANY OVERVIEW 346 TABLE 469 GREINER BIO-ONE INTERNATIONAL GMBH: COMPANY OVERVIEW 347 TABLE 470 LIOFILCHEM S.R.L.: COMPANY OVERVIEW 348 TABLE 471 TITAN BIOTECH LTD.: COMPANY OVERVIEW 349 TABLE 472 BLOOD CULTURE TESTS MARKET: RISK ASSESSMENT 362 FIGURE 1 BLOOD CULTURE TESTS MARKET SEGMENTATION & REGIONAL SCOPE 39 FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 43 FIGURE 3 GLOBAL BLOOD CULTURE TESTS MARKET, 2024–2031 44 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BLOOD CULTURE TESTS MARKET, 2023–2025 44 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BLOOD CULTURE TESTS MARKET 45 FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN BLOOD CULTURE TESTS MARKET, 2026–2031 46 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47 FIGURE 8 RISING BURDEN OF BLOODSTREAM INFECTIONS AND ANTIMICROBIAL RESISTANCE TO DRIVE MARKET GROWTH 48 FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49 FIGURE 10 AUTOMATED BLOOD CULTURES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 49 FIGURE 11 CULTURE-BASED TECHNOLOGIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50 FIGURE 12 BACTEREMIA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50 FIGURE 13 HOSPITAL-LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51 FIGURE 15 BLOOD CULTURE TESTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52 FIGURE 16 BLOOD CULTURE TESTS MARKET: PORTER’S FIVE FORCES ANALYSIS 63 FIGURE 17 BLOOD CULTURE TESTS MARKET: SUPPLY CHAIN ANALYSIS 67 FIGURE 18 BLOOD CULTURE TESTS MARKET: VALUE CHAIN ANALYSIS 68 FIGURE 19 BLOOD CULTURE TESTS MARKET: ECOSYSTEM ANALYSIS 69 FIGURE 20 BLOOD CULTURE TESTS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75 FIGURE 21 NUMBER OF DEALS & FUNDING ACTIVITIES IN BLOOD CULTURE TESTS MARKET 76 FIGURE 22 PATENT ANALYSIS FOR BLOOD CULTURE TESTS, JANUARY 2015–DECEMBER 2025 83 FIGURE 23 MARKET POTENTIAL OF AI IN BLOOD CULTURE TESTS MARKET 86 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 93 FIGURE 25 KEY BUYING CRITERIA, BY OFFERING 94 FIGURE 26 NORTH AMERICA: BLOOD CULTURE TESTS MARKET SNAPSHOT 191 FIGURE 27 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET SNAPSHOT 237 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN BLOOD CULTURE TESTS MARKET, 2023–2025 (USD MILLION) 285 FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BLOOD CULTURE TESTS MARKET, 2025 286 FIGURE 30 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 289 FIGURE 31 BLOOD CULTURE TESTS MARKET: COMPANY FOOTPRINT 290 FIGURE 32 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 293 FIGURE 33 EV/EBITDA OF KEY VENDORS 295 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 296 FIGURE 35 BLOOD CULTURE TESTS MARKET: BRAND/PRODUCT COMPARISON FOR AUTOMATED BLOOD CULTURE SYSTEMS 296 FIGURE 36 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 300 FIGURE 37 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 305 FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2025) 309 FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 313 FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 316 FIGURE 41 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 320 FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2025) 324 FIGURE 43 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025) 328 FIGURE 44 AUTOBIO DIAGNOSTICS CO., LTD.: COMPANY SNAPSHOT (2025) 331 FIGURE 45 BLOOD CULTURE TESTS MARKET: RESEARCH DESIGN METHODOLOGY 350 FIGURE 46 PRIMARY SOURCES 353 FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 355 FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 356 FIGURE 49 GLOBAL BLOOD CULTURE TESTS MARKET: REVENUE SHARE ANALYSIS 357 FIGURE 50 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 358 FIGURE 51 TOP-DOWN APPROACH 359 FIGURE 52 DATA TRIANGULATION METHODOLOGY 360 FIGURE 53 PARAMETRIC ASSUMPTIONS 361

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們